MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Parakinesia brachialis oscitans due to an acute medial cerebral artery stroke

    V. Gadelha, F. Germiniani, M. Lange, F. Nascimento, F. Zorzetto, P. Dos Santos, H. Teive (Curitiba, Brazil)

    Objective: To report the case of a patient with a medial cerebral artery acute stroke who developed parakinesia brachialis oscitans after thrombolysis. Background: Although rare, …
  • 2019 International Congress

    Predicting the efficacy of STN-DBS in patients with different Parkinson’s disease motor subtypes by preoperative total and partial levodopa response

    GH. Lu, ZX. Yin, YW. Jin (Nanchang, China)

    Objective: To better investigate the value of the challenge test by introducing total and partial LR, and explain the clinical significance of 30% LR through…
  • 2019 International Congress

    Kinetic Sensors for Ambulatory Gait and Balance Evaluation in Parkinson’s Disease

    K. Sharma, A. Cucca, R. Sills, J. Jung, A. Feigin, M. Biagioni (New York, NY, USA)

    Objective: To explore the applicability of an ambulatory inertial sensor (G-walk) to characterize gait function during the Timed Up and Go (TUG) Test. Background: In…
  • 2019 International Congress

    The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD

    J. Corey-Bloom, S. Aboufadel, I. Beltran-Najera, C. Snell, M. Williams, P. Gilbert (La Jolla, CA, USA)

    Objective: To examine the usefulness of a new behavioral questionnaire for patients with, and at risk for, Huntington’s disease (HD). Background: Behavioral changes, including apathy,…
  • 2019 International Congress

    Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

    B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)

    Objective: To assess the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD. Background: Huntingtin…
  • 2019 International Congress

    Factors underlying reduced aerobic capacity in Huntington disease

    A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

    Objective: Examine factors underlying aerobic capacity in prodromal and manifest Huntington disease (HD) and matched controls Background: HD results in motor impairments, weight loss, muscle…
  • 2019 International Congress

    The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)

    E. Alvarez, C. Spanaki, E. Pekkonen, L. Manzanares, Y. Liu, O. Sánchez-Soliño, L. Barbato (Elche, Spain)

    Objective: The DYSCOVER study will be the first interventional, randomized study to evaluate the comparative effectiveness of levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment…
  • 2019 International Congress

    Availability of Parkinson’s disease medicines in Ghana: a national survey

    M. Cham, I. Sefah, K. Oppon, R. Odikro, C. Amenorvi, A. Malik, J. Duah, G. Pezzoli, F. Baiden, R. Cilia (Sogakope, Ghana)

    Objective: To determine the affordability, availability, geographic distribution and financing options of Parkinson’s disease (PD) medication in Ghana. Background: In sub-Saharan Africa, patients with PD…
  • 2019 International Congress

    Safety of Iron Chelation in Patients with Brain Iron Overload

    C. Fradette, T. Klopstock, L. Neumayr, I. Karin, G. Zorzi, T. Kmieć, B. Büchner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, F. Zibordi, N. Nardocci, A. Stilman, M. Spino, E. Vichinsky, F. Tricta (Toronto, ON, Canada)

    Objective: To assess the safety of iron chelation in the treatment of regional brain iron overload. Background: Excess brain iron is evident in neurodegenerative diseases…
  • 2019 International Congress

    Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease

    J. Huber, E. Stathopoulos, J. Sussman, K. Richardson, D. Matheron, S. Snyder (West Lafayette, IN, USA)

    Objective: The purpose of the present study was to assess the effects of a device-driven treatment (SpeechVive) on respiratory and laryngeal function after 8 weeks…
  • « Previous Page
  • 1
  • …
  • 144
  • 145
  • 146
  • 147
  • 148
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #23139 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley